Evofem Biosciences, Inc. (EVFM): Depreciation & Amortization

Annual figures by period end, from SEC filings.

Older than the company's other figures. The latest Depreciation & Amortization is for the year ended 2023-12-31, while the company's latest annual report covers the year ended 2025-12-31. Its later filings do not report this line under the concept TickerFacts maps.

$477.0K
Year ended 2023-12-31
+16.5%
3-year compound annual growth
+12.7%
5-year compound annual growth
+20.8%
10-year compound annual growth
$1.02M2013-12-31: $72.2K2014-12-31: $17.7K2015-12-31: $58.4K2016-12-31: $69.1K2017-12-31: $244.0K2018-12-31: $262.0K2019-12-31: $263.0K2020-12-31: $302.0K2021-12-31: $1.02M2022-12-31: $1.01M2023-12-31: $477.0K$477.0K
2013-12-31 Depreciation & Amortization (USD) 2023-12-31
Period endedDepreciation & AmortizationChange YoYSource filing
2023-12-31$477.0K-53.0%2024-03-27, From 2023-01-01
2022-12-31$1.01M-0.8%2024-03-27, From 2022-01-01
2021-12-31$1.02M+238.7%2023-04-27, From 2021-01-01
2020-12-31$302.0K+14.8%2022-03-10, From 2020-01-01
2019-12-31$263.0K+0.4%2021-03-04, From 2019-01-01
2018-12-31$262.0K+7.4%2020-03-12, From 2018-01-01
2017-12-31$244.0K+253.1%2019-03-01, From 2017-01-01
2016-12-31$69.1K+18.3%2018-02-26, From 2016-01-01
2015-12-31$58.4K+230.7%2018-02-26, From 2015-01-01
2014-12-31$17.7K-75.5%2017-03-23, From 2014-01-01
2013-12-31$72.2Kn/a2016-03-29, From 2013-01-01